Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Engineered human gamma delta T cells for multiple myeloma immunotherapy

FY 2019-20

Summary
"Adoptive cell therapy using engineered human T cells can, in many cases, produce a complete response in patients with refractory relapsed hematological malignancies who otherwise lack treatment options. However, the current cost of the commercially available engineered T cell therapies begins at the expensive price of $500,000 CAD, and is consequently not financially sustainable within the Canadian healthcare system. A major cost driver is the inefficient manufacturing process whereby each patient's treatment is individually manufactured from their own T cells, a necessity for the type of T cells currently used in commercial engineered T cell therapies. These therapies are currently manufactured in a T cell subset known as alphaβ T cells, which cause graft versus host disease when delivered to unrelated patients. A separate subset of T cells, γδ T cells, do not cause graft versus host disease and therefore represent a potential off-the-shelf solution that can be mass produced to reduce manufacturing costs. My project will focus on developing chimeric receptor engineered human γδ T cells for Multiple Myeloma as a promising new therapy for the currently incurable hematological malignancy. Our group has designed chimeric receptors that redirect human alphaβ T cells to kill Multiple Myeloma cells through targeting of B Cell Maturation Antigen. I will adapt our existing chimeric receptors for human γδ T cells by augmenting the chimeric receptor intracellular signalling domains to optimize γδ T cell activation and multiple myeloma-specific killing. My ultimate goal is to produce an off-the-shelf engineered human γδ T cell for cancer therapy that will reduce the cost of these expensive therapies and increase the number of patients who can access these exciting treatments. "
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428678
Name
Asbury Sarah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineered human gamma delta T cells for multiple myeloma immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immune System; Allogeneic; Chimeric Antigen Receptor (Car) T Cells; Engineered Adoptive T Cell Therapy; Gamma Delta T Cells; Genetic Engineering; Immunology; Immunotherapy; Multiple Myeloma; Scalable Manufacturing
Abstract
"Adoptive cell therapy using engineered human T cells can, in many cases, produce a complete response in patients with refractory relapsed hematological malignancies who otherwise lack treatment options. However, the current cost of the commercially available engineered T cell therapies begins at the expensive price of $500,000 CAD, and is consequently not financially sustainable within the Canadian healthcare system. A major cost driver is the inefficient manufacturing process whereby each patient's treatment is individually manufactured from their own T cells, a necessity for the type of T cells currently used in commercial engineered T cell therapies. These therapies are currently manufactured in a T cell subset known as alphaβ T cells, which cause graft versus host disease when delivered to unrelated patients. A separate subset of T cells, γδ T cells, do not cause graft versus host disease and therefore represent a potential off-the-shelf solution that can be mass produced to reduce manufacturing costs. My project will focus on developing chimeric receptor engineered human γδ T cells for Multiple Myeloma as a promising new therapy for the currently incurable hematological malignancy. Our group has designed chimeric receptors that redirect human alphaβ T cells to kill Multiple Myeloma cells through targeting of B Cell Maturation Antigen. I will adapt our existing chimeric receptors for human γδ T cells by augmenting the chimeric receptor intracellular signalling domains to optimize γδ T cell activation and multiple myeloma-specific killing. My ultimate goal is to produce an off-the-shelf engineered human γδ T cell for cancer therapy that will reduce the cost of these expensive therapies and increase the number of patients who can access these exciting treatments. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Asbury, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~